Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Michael J. Townsend"'
Autor:
Luz D. Orozco, Hsu-Hsin Chen, Christian Cox, Kenneth J. Katschke, Jr., Rommel Arceo, Carmina Espiritu, Patrick Caplazi, Sarajane Saturnio Nghiem, Ying-Jiun Chen, Zora Modrusan, Amy Dressen, Leonard D. Goldstein, Christine Clarke, Tushar Bhangale, Brian Yaspan, Marion Jeanne, Michael J. Townsend, Menno van Lookeren Campagne, Jason A. Hackney
Publikováno v:
Cell Reports, Vol 42, Iss 3, Pp 112298- (2023)
Externí odkaz:
https://doaj.org/article/50149307557045f491296fd14962a70c
Autor:
Katie Tuckwell, Cem Gabay, Thierry Sornasse, Ruediger Paul Laubender, Jianmei Wang, Michael J. Townsend
Publikováno v:
Advances in Rheumatology, Vol 59, Iss 1, Pp 1-8 (2019)
Abstract Background Tocilizumab (TCZ), a humanized monoclonal antibody against the interleukin-6 receptor, has been proven to be a safe and effective treatment for rheumatoid arthritis (RA). Because RA is a heterogenous disease and patient response t
Externí odkaz:
https://doaj.org/article/f93ee17da4294ee2a6f44abe27180732
Autor:
Luz D. Orozco, Hsu-Hsin Chen, Christian Cox, Kenneth J. Katschke, Jr., Rommel Arceo, Carmina Espiritu, Patrick Caplazi, Sarajane Saturnio Nghiem, Ying-Jiun Chen, Zora Modrusan, Amy Dressen, Leonard D. Goldstein, Christine Clarke, Tushar Bhangale, Brian Yaspan, Marion Jeanne, Michael J. Townsend, Menno van Lookeren Campagne, Jason A. Hackney
Publikováno v:
Cell Reports, Vol 30, Iss 4, Pp 1246-1259.e6 (2020)
Summary: Age-related macular degeneration (AMD) is a leading cause of vision loss. To better understand disease pathogenesis and identify causal genes in GWAS loci for AMD risk, we present a comprehensive database of human retina and retinal pigment
Externí odkaz:
https://doaj.org/article/1d550e817e174a2695fd2849cb2c4767
Autor:
Hans D. Brightbill, Eric Suto, Nicole Blaquiere, Nandhini Ramamoorthi, Swathi Sujatha-Bhaskar, Emily B. Gogol, Georgette M. Castanedo, Benjamin T. Jackson, Youngsu C. Kwon, Susan Haller, Justin Lesch, Karin Bents, Christine Everett, Pawan Bir Kohli, Sandra Linge, Laura Christian, Kathy Barrett, Allan Jaochico, Leonid M. Berezhkovskiy, Peter W. Fan, Zora Modrusan, Kelli Veliz, Michael J. Townsend, Jason DeVoss, Adam R. Johnson, Robert Godemann, Wyne P. Lee, Cary D. Austin, Brent S. McKenzie, Jason A. Hackney, James J. Crawford, Steven T. Staben, Moulay H. Alaoui Ismaili, Lawren C. Wu, Nico Ghilardi
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Clinical trials of BAFF blockade with belimumab have shown partial efficacy for the treatment of systemic lupus erythematosus (SLE), so other therapeutic options are required. Here, the authors present a new small molecule inhibitor that targets NIK
Externí odkaz:
https://doaj.org/article/c1b21708fc0a4c58b4c58242d9d32c50
Autor:
Myles J. Lewis, Michael R. Barnes, Kevin Blighe, Katriona Goldmann, Sharmila Rana, Jason A. Hackney, Nandhini Ramamoorthi, Christopher R. John, David S. Watson, Sarah K. Kummerfeld, Rebecca Hands, Sudeh Riahi, Vidalba Rocher-Ros, Felice Rivellese, Frances Humby, Stephen Kelly, Michele Bombardieri, Nora Ng, Maria DiCicco, Désirée van der Heijde, Robert Landewé, Annette van der Helm-van Mil, Alberto Cauli, Iain B. McInnes, Christopher D. Buckley, Ernest Choy, Peter C. Taylor, Michael J. Townsend, Costantino Pitzalis
Publikováno v:
Cell Reports, Vol 28, Iss 9, Pp 2455-2470.e5 (2019)
Summary: There is a current imperative to unravel the hierarchy of molecular pathways that drive the transition of early to established disease in rheumatoid arthritis (RA). Herein, we report a comprehensive RNA sequencing analysis of the molecular p
Externí odkaz:
https://doaj.org/article/4d8c545c261542bf89b68fd905e05452
Autor:
Kim R. Simpfendorfer, Wentian Li, Andrew Shih, Hongxiu Wen, Harini P. Kothari, Edward A. Einsidler, Arthur Wuster, Julie Hunkapiller, Timothy W. Behrens, Robert R. Graham, Michael J. Townsend, Doron M. Behar, Rui Hu, Elliott Greenspan, Peter K. Gregersen
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 19, Iss , Pp - (2019)
Objectives: The gene encoding glucose transporter 3 (GLUT3, SLC2A3) is present in the human population at variable copy number. An overt disease phenotype of SLC2A3 copy number variants has not been reported; however, deletion of SLC2A3 has been prev
Externí odkaz:
https://doaj.org/article/3acbee21fb1b430b93d5f749508543c9
Autor:
Christopher McBride, Lynnie Trzoss, Davide Povero, Milos Lazic, Geza Ambrus-Aikelin, Angelina Santini, Rama Pranadinata, Gretchen Bain, Ryan Stansfield, Jeffrey A. Stafford, James Veal, Ryan Takahashi, Justin Ly, Shu Chen, Liling Liu, Marika Nespi, Robert Blake, Arna Katewa, Tracy Kleinheinz, Swathi Sujatha-Bhaskar, Nandhini Ramamoorthi, Jessica Sims, Brent McKenzie, Mark Chen, Mark Ultsch, Matthew Johnson, Jeremy Murray, Claudio Ciferri, Steven T. Staben, Michael J. Townsend, Craig E. Stivala
Publikováno v:
Journal of Medicinal Chemistry. 65:14721-14739
Autor:
Nadia M T Roodenrijs, Paco M J Welsing, Joël van Roon, Jan L M Schoneveld, Marlies C van der Goes, György Nagy, Michael J Townsend, Jacob M van Laar
Publikováno v:
Rheumatology. 61:3552-3566
Management of RA patients has significantly improved over the past decades. However, a substantial proportion of patients is difficult-to-treat (D2T), remaining symptomatic after failing biological and/or targeted synthetic DMARDs. Multiple factors c
Autor:
Luz D. Orozco, Leah Owen, Jeffrey Hofmann, Amy D. Stockwell, Jianhua Tao, Susan Haller, Vineeth T. Mukundan, Christine Clarke, Jessica Lund, Akshayalakshmi Sridhar, Julie L. Barr, Rylee A. Zavala, Elijah C. Graves, Charles Zhang, Nadine Husami, Robert Finley, Elizabeth Au, John H. Lillvis, Michael H. Farkas, Akbar Shakoor, Richard M. Sherva, Ivana K. Kim, Joshua S. Kaminker, Michael J. Townsend, Lindsay A. Farrer, Brian L. Yaspan, Hsu-Hsin Chen, Margaret M. DeAngelis
Age-related Macular Degeneration (AMD) is a leading cause of blindness, affecting 200 million people worldwide. We present a comprehensive molecular atlas for different stages of AMD.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a07fcd58dd2422fa1d90174ae6aa8727
Autor:
Rupal Desai, Pedro C. Miranda, Anna Maura Fernandes, Viviane A de Souza, Nicholas S. Jones, Juan J Jaller-Raad, Rodrigo Garcia Salinas, Pascal Guibord, Balazs Toth, Jason A. Hackney, Chin Lee, Katie Tuckwell, Leslie W. Chinn, Richard Furie, Armend Lokku, Nandhini Ramamoorthi, Julie Rae, David A. Isenberg, Michael J. Townsend, Olivia Hwang, A. Mcgregor, Joshua Galanter, Alyssa Morimoto
Publikováno v:
Arthritis & Rheumatology. 73:1835-1846
Objective Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed in this phase I